Galectin Therapeutics Inc. (GALT) Stock

Galectin Therapeutics Inc., a clinical stage biopharmaceutical firm, specializes in the research and development of treatments targeting fibrotic diseases, cancer, and other medical conditions. At the forefront of its pipeline is belapectin (GR-MD-02), a galectin-3 inhibitor derived from a galactoarabino-rhamnogalacturonan polysaccharide polymer. Currently in Phase III clinical trials, belapectin shows promise for treating liver fibrosis associated with non-alcoholic steatohepatitis cirrhosis and fatty liver disease, as well as exploring its potential in cancer therapy.

In addition to belapectin, Galectin Therapeutics is advancing GM-CT-01 through pre-clinical development stages. This candidate targets cardiac and vascular fibrosis, further broadening the company's therapeutic portfolio. Galectin Therapeutics also aims to expand belapectin's applications to include treating psoriasis, lung fibrosis, and kidney fibrosis, demonstrating its commitment to addressing diverse medical needs through innovative drug development.

Founded in 2000 and headquartered in Norcross, Georgia, Galectin Therapeutics Inc. was originally known as Pro-Pharmaceuticals, Inc. before rebranding in May 2011. The company collaborates through Galectin Sciences, LLC, a joint venture with SBH Sciences, Inc., focusing on developing small organic molecule inhibitors of galectin-3 for oral administration. With a robust research pipeline and strategic partnerships, Galectin Therapeutics remains dedicated to advancing novel therapies and enhancing patient outcomes in the field of biopharmaceuticals.